InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,699.61
(
-0.25%
)
US TECH 100
19,331.40
(
-0.02%
)
Dow Jones
41,951.67
(
-0.17%
)
Brent Oil
73.68
(
-0.87%
)
Bitcoin
62,866.61
(
-0.13%
)
Post# of 61
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

RealGenius

Send PM Follow Ignore
Followers 91
Posts 1956
Boards Moderated 0
Alias Born 07/31/2013

RealGenius

Re: None

Sunday, 03/01/2015 2:03:53 AM

Sunday, March 01, 2015 2:03:53 AM

Post# of 61
Strategic: The Company believes that it has sufficient cash to fund its current activities into 2016. Biotie continues to consider financing options to fully fund the tozadenant Phase 3 program to approval. The Phase 2 studies with SYN120 and BTT1023 are funded largely with non-dilutive financing, and top-line data from the SYNAPSE study is expected in the second half of 2016.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up